Alumis Inc
ALMS4.080USD
-0.050-1.21%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
221.98MCap. mercado
PérdidaP/E TTM
Más Datos de Alumis Inc Compañía
Alumis Inc. is a clinical-stage biopharmaceutical company. It develops two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. It builds a pipeline of molecules with the potential to address a range of immune-mediated diseases as monotherapy or combination therapies. ESK-001 is an allosteric TYK2 inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus and Uveitis. A-005 as a CNS-penetrant, allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a range of neuroinflammatory and neurodegenerative diseases. It has several early-stage discovery assets, such as targets identified by its data analytics platform, for the potential treatment of immune-mediated indications. Its data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the CNS.
Información de la empresa
Símbolo de cotizaciónALMS
Nombre de la empresaAlumis Inc
Fecha de salida a bolsaJun 28, 2024
Director ejecutivoMr. Martin Babler
Número de empleados168
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 28
Dirección280 East Grand Avenue
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16502316625
Sitio Webhttps://www.alumis.com/
Símbolo de cotizaciónALMS
Fecha de salida a bolsaJun 28, 2024
Director ejecutivoMr. Martin Babler
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Director
Independent Director
--
--
Dr. Srinivas Akkaraju, M.D., Ph.D.
Dr. Srinivas Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Roy C. Hardiman, J.D.
Mr. Roy C. Hardiman, J.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Martin Babler
Mr. Martin Babler
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
106.45K
--
Mr. Mark Bradley
Mr. Mark Bradley
Chief Development Officer
Chief Development Officer
48.73K
+121.71%
Mr. Derrick Richardson
Mr. Derrick Richardson
Senior Vice President - People and Culture
Senior Vice President - People and Culture
42.80K
--
Mr. John R. Schroer
Mr. John R. Schroer
Chief Financial Officer
Chief Financial Officer
28.00K
--
Dr. Jorn Drappa, M.D., Ph.D.
Dr. Jorn Drappa, M.D., Ph.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
25.45K
--
Mr. Patrick (Pat) Machado, J.D.
Mr. Patrick (Pat) Machado, J.D.
Independent Director
Independent Director
7.06K
--
Desglose de ingresos
FY2025Q1
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
17.39M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 29 de jul
Actualizado: mar., 29 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
Accionistas
Accionistas
Proporción
Foresite Capital Management, LLC
15.83%
Ayur Maya Capital Management Company, L.P.
15.77%
Samsara BioCapital, LLC
5.00%
VenBio Partners LLC
2.90%
Cormorant Asset Management, LP
2.24%
Other
58.26%
Tipos de accionistas
Accionistas
Proporción
Private Equity
34.50%
Venture Capital
7.06%
Investment Advisor
5.68%
Hedge Fund
4.34%
Investment Advisor/Hedge Fund
2.14%
Individual Investor
0.64%
Bank and Trust
0.43%
Research Firm
0.34%
Sovereign Wealth Fund
0.21%
Other
44.65%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
149
53.14M
55.36%
+11.35M
2025Q1
136
45.24M
77.97%
+3.71M
2024Q4
112
45.08M
95.45%
+8.63M
2024Q3
90
35.83M
75.90%
+3.97M
2024Q2
36
30.85M
69.04%
+30.85M
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Foresite Capital Management, LLC
15.20M
15.83%
+5.22M
+52.25%
May 21, 2025
Ayur Maya Capital Management Company, L.P.
15.14M
15.77%
+4.49M
+42.21%
May 21, 2025
Samsara BioCapital, LLC
4.80M
5%
+1.53M
+46.99%
May 21, 2025
VenBio Partners LLC
2.79M
2.9%
--
--
Mar 31, 2025
Cormorant Asset Management, LP
2.15M
2.24%
--
--
Mar 31, 2025
SR One Capital Management, LP
1.96M
2.04%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
1.56M
1.63%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
1.48M
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.35M
1.41%
+300.30K
+28.57%
Mar 31, 2025
The Vanguard Group, Inc.
937.20K
0.98%
+99.01K
+11.81%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Biotechnology ETF
0.02%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
Ver más
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
iShares Micro-Cap ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
iShares Biotechnology ETF
Proporción0.02%
ProShares Hedge Replication ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0.01%
Proshares Ultra Russell 2000
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
